Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in Phase 2 and 3 clinical trials

Sustained virologic response at posttreatment Week 12 (SVR12) is the widely accepted efficacy endpoint for direct‐acting antiviral agents. Those with hepatitis C virus (HCV) are presenting younger with milder liver disease, potentially reducing need for long‐term liver posttreatment monitoring. This...

Descripción completa

Detalles Bibliográficos
Autores principales: Gane, Edward, de Ledinghen, Victor, Dylla, Douglas E., Rizzardini, Giuliano, Shiffman, Mitchell L., Barclay, Stephen T., Calleja, Jose Luis, Xue, Zhenyi, Burroughs, Margaret, Gutierrez, Julio A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292745/
https://www.ncbi.nlm.nih.gov/pubmed/34448313
http://dx.doi.org/10.1111/jvh.13600

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292745/
https://www.ncbi.nlm.nih.gov/pubmed/34448313
http://dx.doi.org/10.1111/jvh.13600

Ejemplares similares